About RHYTHM AI

About company

RHYTHM AI is founded on world-leading research from Barts Heart Centre, London, UK and focused on the $5bn Atrial Fibrillation (AF) market and is forecasted to be $18bn by 2026 (16% CAGR).The lead product is the STAR Mapping System™ which proof of concept studies demonstrate improvements in the outcome of Ablation procedures in for patients with persistent AF. Rhythm AI holds an exclusive global licence to develop and commercialise STAR Mapping™.